Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 622

Similar articles for PubMed (Select 19058905)

1.

Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.

Jansen FH, Roobol M, Jenster G, Schröder FH, Bangma CH.

Eur Urol. 2009 Mar;55(3):563-74. doi: 10.1016/j.eururo.2008.11.040. Epub 2008 Nov 29. Review.

PMID:
19058905
2.

Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.

Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Huber A, Lümmen G, Tscholl R.

Urology. 2000 Apr;55(4):481-5.

PMID:
10736487
4.

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.

Haese A, Graefen M, Steuber T, Becker C, Pettersson K, Piironen T, Noldus J, Huland H, Lilja H.

Prostate. 2001 Oct 1;49(2):101-9.

PMID:
11582588
5.

Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA).

Martin BJ, Finlay JA, Sterling K, Ward M, Lifsey D, Mercante D, Jainto JM, Martin L, Rayford W.

Prostate Cancer Prostatic Dis. 2004;7(2):132-7.

PMID:
15007379
6.

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.

Becker C, Piironen T, Pettersson K, Hugosson J, Lilja H.

J Urol. 2003 Oct;170(4 Pt 1):1169-74.

PMID:
14501718
8.

[Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis].

Lein M, Stephan C, Jung K, Schnorr D, Loening SA.

Urologe A. 2000 Jul;39(4):313-23. Review. German.

PMID:
10957772
9.

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.

Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H, Sokoll LJ, Partin AW.

J Urol. 2005 Mar;173(3):752-6.

PMID:
15711262
10.

Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.

Stephan C, Jung K, Soosaipillai A, Yousef GM, Cammann H, Meyer H, Xu C, Diamandis EP.

BJU Int. 2005 Sep;96(4):521-7.

PMID:
16104903
11.

Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.

Naya Y, Fritsche HA, Bhadkamkar VA, Mikolajczyk SD, Rittenhouse HG, Babaian RJ.

Urol Oncol. 2005 Jan-Feb;23(1):16-21.

PMID:
15885578
12.

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.

Steuber T, Niemela P, Haese A, Pettersson K, Erbersdobler A, Felix Chun KH, Graefen M, Kattan MW, Huland H, Lilja H.

Prostate. 2005 Apr 1;63(1):13-8.

PMID:
15378521
13.

Percent free PSA as an additional measure in a prostate cancer screen.

Miele ME.

Clin Lab Sci. 2001 Spring;14(2):102-7.

PMID:
15625982
14.

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.

Vickers AJ, Ulmert D, Serio AM, Björk T, Scardino PT, Eastham JA, Berglund G, Lilja H.

Int J Cancer. 2007 Nov 15;121(10):2212-7.

PMID:
17657743
15.

Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?

Jung K, Stephan C, Elgeti U, Lein M, Brux B, Kristiansen G, Rudolph B, Hauptmann S, Schnorr D, Loening SA, Sinha P.

Int J Cancer. 2001 Sep 1;93(5):759-65.

PMID:
11477592
16.

Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.

Naya Y, Fritsche HA, Bhadkamkar VA, Mikolajczyk SD, Rittenhouse HG, Babaian RJ.

Urology. 2004 Mar;63(3):492-8.

PMID:
15028444
17.

The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.

Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R.

Cancer. 1998 Dec 15;83(12):2540-7.

PMID:
9874461
18.

Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.

Jung K, Hoesel W, Reiche J, Deger S, Kramer J, Loening SA, Lein M, Stephan C.

Urology. 2007 Feb;69(2):320-5.

PMID:
17320672
20.

Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.

Toubert ME, Guillet J, Chiron M, Meria P, Role C, Schlageter MH, Francois H, Borschneck C, Nivelon F, Desgrandchamps F, Rastel D, Cussenot O, Teillac P, Le Duc A, Najean Y.

Eur J Cancer. 1996 Nov;32A(12):2088-93.

PMID:
9014750
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk